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Abstract
Sex chromosome trisomies (SCTs) (XXX, XXY, and XYY karyotypes) are associated with
an elevated risk of neurodevelopmental disorders. The range of severity of the pheno-
type is substantial. We considered whether this variable outcome was related to the
presence of copy number variants (CNVs)—stretches of duplicated or deleted DNA. A
sample of 125 children with an SCT were compared with 181 children of normal kar-
yotype who had been given the same assessments. First, we compared the groups on
measures of overall CNV burden: number of CNVs, total span of CNVs, and likely
functional impact (probability of loss-of-function intolerance, pLI, summed over CNVs).
Differences between groups were small relative to within-group variance and not sta-
tistically significant on overall test. Next, we considered whether a measure of general
neurodevelopmental impairment was predicted by pLI summed score, SCT versus com-
parison group, or the interaction between them. There was a substantial effect of
SCT/comparison status but the pLI score was not predictive of outcomes in either
group. We conclude that variable presence of CNVs is not a likely explanation for the
wide phenotypic variation in children with SCTs. We discuss methodological challenges
of testing whether CNVs are implicated in causing neurodevelopmental problems.
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1 | INTRODUCTION
Children who carry an extra X or Y chromosome do not have
any gross physical or mental abnormalities; however, there is a pro-
nounced increase in the risk of language disorders and autism (Bishop
et al., 2011). Investigation of the genetic correlates of language and
communication in children with sex chromosome trisomies (SCT) may
help understand the phenotypic variation seen in affected individuals
and could also lead to improved understanding of common neu-
rodevelopmental disorders in children with a typical karyotype. A
notable feature of SCT is the variability of the cognitive phenotype,
which is substantial in all three forms of SCT: trisomy X (47, XXX),
Klinefelter syndrome (47, XXY), and XYY karyotype also known as
Jacobs syndrome (47, XYY) (Bishop et al., 2011, 2019; Wilson, King &
Bishop, 2019). Some children have severe difficulties including intel-
lectual disability, behavioral problems, or autism spectrum disorder
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(ASD), while others have little or no evidence of neurodevelopmental
problems.
Such heterogeneity is a common feature of genetic neu-
rodevelopmental syndromes, even between individuals who carry the
same causative genetic variant. A range of explanations have been
proposed for this high level of phenotypic variability. Veltman and
Brunner (2010) suggested the “two-hit” hypothesis in which genetic
rearrangements can combine with a secondary variant to amplify the
impact of a microdeletion syndrome. Bishop and Scerif (2011)
extended this hypothesis to SCTs to develop a “double hit” model that
refers specifically to SCTs. In this particular case, the secondary vari-
ant is carried in a region that is common to both the X and Y chromo-
somes and maintains expression of both gene copies (gametologues).
They focused on a specific pathway which includes neurexin and
neuroligin genes, as this network has previously been associated with
synaptic formation and language disorders. Newbury, Simpson,
Thompson and Bishop (2018) tested the “double hit” hypothesis,
which maintains that the presence of an extra dose of neuroligin asso-
ciated with overexpression of NLGN4 on X and Y chromosomes could
amplify the impact of genetic variants (both on the sex chromosomes
and autosomes) that normally create only a minor risk for neu-
rodevelopmental abnormalities. They did not, however, find any sup-
port for that hypothesis from investigation of common variants in
either of the two candidate genes CNTNAP2 and NRXN1.
In the current article, we consider a possible “double hit” mechanism
in which an extra sex chromosome could amplify genetic risk, by inter-
acting with copy number variants (CNVs). The history of recognition of
CNVs is documented by Beckmann et al. (2007): these are deletions or
insertions affecting chunks of DNA 1 kb in length or larger, which were
first described in the 1960s and 1970s. It was a few decades later before
it was recognized that this kind of large-scale submicroscopic variation is
common across the genome and not necessarily pathological. Neverthe-
less, where CNVs are large and/or affect the function of key genes, they
are likely to be associated with neurodevelopmental disorders, notably
intellectual disability (Coe et al., 2014) and ASD (Sanders et al., 2015).
One study also found an association with severe developmental lan-
guage disorder (DLD) (Kalnak et al., 2018).
Because they are more likely to have pathogenic effects, large, dis-
ruptive CNVs tend to be relatively rare in populations. However, the
constraints upon smaller CNVs may be less pronounced and, as such,
these are more commonly observed. Simpson et al. (2015) found that
there was a slight increase in total CNV “burden” (i.e., cumulative size of
all CNVs across the genome) in cases of DLD and their relatives, com-
pared to a comparison sample. The fact that unaffected relatives showed
the increase as well as affected individuals suggested that an increased
number of CNVs may play a cumulative role in mediating an increased
risk of language disorder, but the precise impact may depend on the
location and extent of the CNV, and whether it disrupts gene function.
The specific combination of inherited events may also be important.
Here, we consider the role of CNVs in moderating neu-
rodevelopmental outcomes in children carrying SCTs. We explore two
hypotheses. The epistasis hypothesis predicts that the risk of neu-
rodevelopmental disorder associated with a CNV will be increased
when there is a trisomy, because of interactions between CNVs and
the overexpression of genes on the sex chromosomes. This relates to
the idea of a two-hit model (Veltman & Brunner, 2010), whereby the
effect of a microdeletion is not deterministic, but rather acts as a
risk factor that can increase the impact of deletions or duplications
elsewhere on the genome. This kind of mechanism is supported by
Girirajan et al. (2010) who found that individuals with severe neu-
rodevelopmental disorders associated with a deletion on chromosome
16p12.1 often had a second autosomal CNV. A genomic alteration
that may have little or no effect in an unaffected relative appeared to
have a particularly detrimental effect in combination with a second
“hit.” We extend this idea to encompass the notion that the impact
of a third copy of a sex chromosome may be amplified by a CNV
that might have little effect in a child with a normal complement of
chromosomes.
Alternatively, a quite different hypothesis—the burden hypothesis—
maintains there is an increased number of CNVs in individuals with
SCTs, across the entire genome. According to this hypothesis, the high
rate of neurodevelopmental problems could be a direct consequence of
an increased number of CNVs—perhaps because whatever mechanism
leads to a trisomy also disrupts CNV checkpoints.
The best source of evidence for an increased number of CNVs in
SCT cases comes from Rocca et al. (2016), who presented evidence
that men with Klinefelter syndrome (47, XXY) had an unusually high
number of X-chromosome CNVs. They compared CNVs on the X-
chromosome in 94 men with Klinefelter (47, XXY) syndrome to that in
85 controls (43 males and 42 females), and reported a higher number
of CNVs, especially duplications, in the Klinefelter group. Thirty-nine
of them (41.5%) carried CNVs, compared to 12/42, (28.6%) of control
females, and 8/43, (18.6%) of control males. As the authors noted, the
presence of additional CNVs (either in terms of burden, or specific
CNVs that “hit” complementary genetic pathways) in some individuals
could provide an explanation for the variable phenotype, but they did
not test for associations with phenotype in their sample. Their study
raised the further question of whether an increased rate of CNVs
might be seen in other SCTs—XXX and XYY—and whether these
might be found on the autosomes as well as the X-chromosome.
Further circumstantial evidence for the burden hypothesis and the
impact of CNVs in cases of SCT comes from Le Gall et al. (2017), who
focused on a group of 14 patients with SCTs in whom an additional
causative autosomal copy number event was suspected because of an
unusually severe phenotype involving intellectual disability or other
severe developmental disorder. They found seven patients carried a
pathogenic CNV (one with Williams–Beuren syndrome, one with
7q11.23 duplication, one with 17q12 duplication, three with 16p11.2
duplication and one with a 15q11.3 deletion). It is important to note
that the breakpoints of individual CNVs vary between cases, and that
for example the three 16p11.2 duplications will differ in their start and
stop point in the genome. They additionally reported that two further
cases carried likely pathogenic CNVs and five carried a CNV of uncer-
tain significance. Because their report focused only on cases with a
known additional micro-deletion or -duplication, the authors were not,
however, able to estimate the prevalence of additional pathogenic
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CNVs in cases of SCT, or to show that a CNV was specifically related
to the severity of the phenotype.
2 | METHODOLOGICAL CONSIDERATIONS
2.1 | Measurement of CNVs
The simplest approach to measuring CNV burden is to count the num-
ber of such events. However, each individual CNV event can vary
substantially in size, and we would expect the total extent of coverage
of all CNVs to also be important. Within the “burden” model, large
and rare CNVs have been shown to be related to the incidence
of neurodevelopmental disorder, presumably because larger events
have a higher likelihood of affecting important genes. Moreover,
larger events in the wider CNV literature are correlated with more
severe clinical presentation (Girirajan et al., 2010). Furthermore, the
impact of a CNV will depend on whether or not it affects the function
of a dosage sensitive gene. More recently, large population sequence
data have allowed the development of gene dosage-sensitivity mea-
sures such as the pLI score (probability of being loss-of-function intol-
erant) reported in the Exome Aggregation Consortium database
(ExAC: http://exac.broadinstitute.org/) (Lek et al., 2016). This metric
is based upon the observed frequency of loss-of-function variants in
population control data compared to that expected given the gene
size. A small event that disrupts a dosage sensitive gene could have
a much higher burden than a large event that affects a large number
of dosage-insensitive genes. A pLI score of ≥0.9 is indicative of
haploinsufficiency and, as such, the metric shows constraint of the
genetic sequence which, in turn, indicates that loss of function of that
gene will affect development.
Given all these considerations, it can be difficult to settle on a
measure for testing for the hypotheses outlined above. Given the
functional validity of the pLI measure, we decided a priori that our pri-
mary measure of burden should be the total pLI score of all the genes
affected by the CNV event.
2.2 | Selection of a study sample
Because many CNVs are found in asymptomatic individuals, we can only
interpret potential relevance of CNV burden for neurodevelopmental
disorders if we have a comparison sample without any disorder.
Although there are databases of medically relevant CNVs (DECIPHER,
ClinVar), these usually only represent extremely rare and pathogenic
changes. More recently, large (N > 14,000) population samples have
become available through gnomAD v3.0 (Collins et al., 2019). However,
neither SNP arrays nor genomic sequencing methods directly measure
the number of copies of a given genetic region. Information regarding
CNVs therefore has to be inferred from such data. It is often problem-
atic to compare samples assessed using whole genome sequencing
methods to the array-based methods applied here. Ideally, we need a
target group and a comparison sample processed together using the
same methods, to help establish whether the rate, extent, or functional
impact of CNVs is unusually high in the target group.
In the current study, a sample of twin children tested on the same
psychometric battery and genotyped in the same experimental data
set as the children with SCTs acted as a comparison sample. However,
this comparison was complicated by the fact that the twin children
had been selected to over-represent cases with DLD. Furthermore,
the SCT sample included some children whose trisomy was only dis-
covered when they were investigated for neurodevelopmental prob-
lems. Thus, the sampling method might have biased both samples in
the direction of finding high rates of CNVs. In practice, this proved
not to have an effect, but we present data for the subset with rela-
tively low bias (see below for definition), as well as the full sample, to
demonstrate that this potential confound did not affect our results.
2.3 | Measure of the phenotype
The “double hit” hypothesis predicts that CNV burden will have a dis-
proportionate impact on the phenotype in children with SCTs. In testing
this hypothesis, we focused on a measure of global neurodevelopmental
impairment, as this would be sensitive to the conditions that are usually
associated with CNVs: intellectual impairment and autism.
2.4 | Aims of the current study
The aims of this article were twofold; first, we aimed to test the “bur-
den” hypothesis. In doing so, we extend previous analyses by Rocca
et al. (2016) by including three subtypes of trisomy: 47, XXX, 47, XXY,
and 47,XYY. We investigated CNVs on the autosomes as well as the
X chromosome. Second, we consider the “epistasis” hypothesis, test-
ing the prediction that the severity of neurodevelopmental problems
will be related to an increased burden of CNV events affecting gene
function.
3 | MATERIALS (SUBJECTS) AND
METHODS
All methods were registered on Open Science Framework Preregistra-
tion (https://osf.io/u2j97). The participant phenotyping and genome-
wide SNP array data were generated for the companion study and are
described in detail in Newbury, Simpson, Thompson, and Bishop (2018).
3.1 | SCT group recruitment
SCT cases aged from 5 to 16 years were recruited from among partici-
pants in a previous study (Bishop et al., 2011) who had agreed to be
re-contacted. Additional participants were recruited via support groups
(Unique: the Rare Chromosome Support Group, and the Klinefelter
Syndrome Association), National Health Service Clinical Genetics
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Centers, and self-referred through the research project Facebook page
or website. In order to be eligible for the study, SCT group participants
had to have a genetic diagnosis of either XXX, XXY, or XYY, and be
fully aware of their genetic status.
Table 1 shows the numbers of children with SCTs in relation to
the type of trisomy and the reason for diagnosis. We distinguish here
between those diagnosed in the course of investigations for neu-
rodevelopmental disorder, who are referred to as “High bias”, and the
remainder, the “Low bias” group, who were diagnosed either in the
course of pre-natal screening, or during investigations for medical
conditions. Both groups combined can be used to test predictions
about CNV/phenotype associations, but the Low bias group is more
suitable for estimating the typical CNV burden associated with SCTs.
3.2 | Comparison group
The comparison group of twin children had been previously recruited
for a study of DLD and laterality (Wilson & Bishop, 2018) and had
undergone the same test battery as the SCT group. We aimed to
recruit a sample where around 75% pairs would include at least one
twin with DLD. This was achieved by selecting cases for inclusion on
the basis of parental response on a telephone interview: any mention
of language delay, history of speech and language therapy, current
language problems or dyslexia was coded as “parental concern.” This
sample therefore represents a DLD enriched group rather than a typi-
cally developing group. Some twin children had evidence of ASD
(N = 15) or intellectual disability (N = 3), and 12 failed a hearing screen
on the day of testing, although none of them had any known sensori-
neural hearing loss. For the current study, because we were interested
in a broader phenotype than pure DLD, these cases were retained in
the sample. One twin from each pair was randomly selected to ensure
independent observations. When comparing rates of CNV burden
with SCT cases, we distinguished between twins selected for having
language problems and those whose parents had not expressed any
concern about language development.
The number of cases that passed both genotyping and CNV call-
ing quality control (see below) are shown in Table 1, subdivided by
karyotype and whether or not they were recruited from a biased
source (i.e., either trisomy cases whose trisomy was discovered in the
course of investigations for neurodevelopmental/behavioral prob-
lems, or twins whose parents volunteered for the study because of
concerns about language development in one or both twins).
3.3 | Test battery
The test battery is described in detail by Newbury et al. (2018). The
battery was designed to provide a quantitative estimate of language,
literacy and communication ability in children aged 5–16 years. In addi-
tion, parents completed a telephone interview, and were invited to
complete two questionnaires and an online diagnostic interview. Our
primary phenotype outcome measure is a scale devised for the study
by Newbury et al. (2018), the global index of neurodevelopmental
impairment (GNI). GNI is an ad hoc measure that combines all available
information about a range of neurodevelopmental disorders affecting
language, attention, social communication and overall functioning (see
Table 2). Scores ranged from 0 (no impairment) to 6 (high impairment).
This was judged to be the most appropriate measure, given that CNVs
have previously been associated most strongly with severe problems
affecting behavior as well as language and cognitive functioning.
In response to reviewer request, we also report exploratory ana-
lyses of two more specific phenotypic measures in relation to CNV bur-
den: language factor scores and Performance IQ (PIQ). The language
factor is derived from tests of Oromotor Skills, Verbal Comprehension,
Vocabulary, and Sentence Repetition (see Newbury et al., 2018, for
details), where a lower score indicates lower language abilities. The PIQ
measure is based on the Wechsler Abbreviated Scale of Intelligence
(Wechsler, 1999).
3.4 | Genetic measures
Genomic DNA was collected and extracted from saliva samples (OG-
500, DNA Genotek) using the manufacturer recommended protocol.
Samples were genotyped using the genome-wide SNP array Infinium
TABLE 1 Numbers of children by karyotype and ascertainment bias
Variable
Comparison group Sex chromosome trisomy group
XY XX XXX XXY XYY
N 99 82 40 42 43
Mean (SD) age (months) 106.7 (19.9) 106 (18.6) 135.1 (47.9) 141.6 (43) 120.6 (40.9)
% White 93 95 88 79 98
% High biasa – – 30 55 58
% With language concernsb 42 20 – – –
Mean (SD) GNIc 1.5 (1.5) 0.8 (1.2) 2.9 (1.9) 2.5 (1.6) 3.0 (1.9)
aSCT cases where trisomy identified during investigations for neurodevelopmental/behavioral disorders.
bTwin from a pair that was recruited because one or both twins had language problems.
cIndex of global neurodevelopmental impairment (see Table 2).
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Global Screening Array-24(v1) targeting 692,824 common and rare
SNPs suitable for both genotyping and CNV analysis. Genotypes had
been previously called for Newbury et al. (2018) using Illumina
GenomeStudio v.2.03, and individual SNPs with a GenTrain (quality)
score of <0.5 and samples with <0.9 of SNPs called were excluded.
Beta allele frequencies and log2 ratio for each of the remaining SNPs
were exported to a .csv file. Autosomal CNV calling was performed
using two separate methods; QuantiSNP (Colella et al., 2007) and
PennCNV (Wang et al., 2007). PennCNV analysis required generation
of an array specific PFB file which was built using the gnomAD whole
genome Non-Finnish European frequency file (hg19) built for use in
Annovar (Wang, Li, & Hakonarson, 2010). This PFB file is available in
the study repository (https://osf.io/rgqwp/). Samples flagged by Penn-
CNV or QuantiSNP as having failed CNV calling quality control were
excluded from analysis.
CNV regions which overlap between the two methods by at least
50% were identified using bedtools v2.27.0 (Quinlan & Hall, 2010) and
retained for further analyses as “high-confidence” CNV calls. The over-
lapping regions were used as start and end positions for CNVs. Calls
that overlapped with highly repetitive immunoglobin, centromeric or
telomeric regions by ≥50% were excluded from analysis. Adjacent CNV
calls located within ≤20% of each other with matched CN state were
merged into one CNV call, accounting of the bias of the algorithms to
conservatively call multiple CNVs in place of one large CNV call.
Chromosome X required a different approach due to the technical
difficulty in accurately calling CNVs in XXX individuals. CNVs overlapping
with immunoglobin, centromeric, telomeric and pseudoautosomal
regions by ≥50% were excluded from analysis. CNVs on the X chromo-
some were called using the Illumina GenomeStudio v.2.03 CNV algo-
rithm, were visually inspected, and then cross referenced to the output
from PennCNV. Events of the X chromosome were called in XX and
XXY individuals (expected CN state = 2 and deletions are CN state = 1
and duplications CN state = 3), and in XY and XYY (expected CN state = 1,
and deletions are CN state = 0 and duplications CN state = 2) individuals.
CNV calls on the chromosome X were not included in the association
analyses due to inability to call duplications in XXX participants, and dele-
tions (CN state = 2) rendering them effectively wildtype at these sites.
Resulting CNV regions containing at least five consecutive
SNPs were annotated using ANNOVAR (2018Apr16 release) (Wang
et al., 2010). CNVs annotated as overlapping at least one gene, inclu-
sive of exons, introns, untranslated regions and non-coding genes,
were retained for further analysis. Sum of pLI (sum_pLI) scores from
each gene within a CNV region were calculated for each individual in
R (code available at https://osf.io/rgqwp/).
3.5 | Power analysis
Our study is constrained by the numbers we were able to recruit, with
further loss of cases which did not pass genotyping quality control. As
explained in our preregistration, the power to detect given effect
sizes in the current study was computed by simulation of correlated
datasets based on our existing sample size. With this sample we are
adequately powered to detect a correlation around .35 between CNV
burden and phenotype in the SCT group.
3.6 | Statistical methods and visualization
Burden metrics, in terms of the number of CNVs, cumulative CNV
span, and a pLI index were calculated for each individual and analyzed
for group differences (SCTs against comparison individuals). We had
pre-registered a Wilcoxon test for group comparisons, but this did not
allow computation of exact probabilities because there were a very
large number of ties. We therefore also calculated exact probabilities
using a permutation test. Empirical p-values were calculated using
10,000 permutations and adjustments for multiple testing used the
Benjamini–Yekutieli procedure. The analysis script is available on
Open Science Framework (https://osf.io/rgqwp/).
The odds ratio was calculated using MedCalc's Odds Ratio Calcu-
lator (www.medcalc.org/calc/).
3.7 | Reporting of pathogenic events
As a side-product of the calling of CNVs, necessary for the calculation
of burden metrics, we were able to identify putative pathogenic events
TABLE 2 Index of global neurodevelopmental impairment
All available information was used to create a single scale reflecting
global level of neurodevelopmental impairment ranging from 0 (no
impairment) to 6 (severe problems). Data from initial parental
telephone interview were available for all children. Data from
language testing were available for all but two very low-functioning
children, who were unable to attempt our tasks. Data from the
Social Responsiveness Scale (SRS) were available for 127 of 143
children with SCTs, and 316 of 388 comparison children. DSM5
diagnoses from the online Development and Well-being
Assessment (DAWBA; Goodman et al., 2000) were available for 89
children with SCTs and 276 comparison children. We used all
available data for each child to create a scale by adding points as
specified below, with maximum score of 6a. Note that some
categories are mutually exclusive (e.g., dyslexia and low PIQ).
• History of speech problems (assessed or treated by
speech-language therapist at preschool age) = 1
• Schooling: Current help in mainstream school (support or special
class or speech-language therapy) = 1; OR attends special
school = 2
• Dyslexia (at least two reading tests >1 SD below mean,
PIQ > 70) = 1
• DLD (Woodcock-Johnson comprehension + at least one other oral
language test >1 SD below mean, PIQ > 70) = 1
• ADHD (parental report or DAWBA diagnosis) = 1
• Behavior problems (DAWBA diagnosis of conduct disorder or clear
description on interview) = 1
• Autism: Report from interview of definite diagnosis, or SRS = 90,
or DAWBA diagnosis = 2
• Low IQ (PIQ < 70 or refusal/inability to do battery) = 1
aIn our previous report by Newbury et al. (2018), this scale was inverted
so a low score corresponded to impairment.
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that occurred in SCT probands and comparison individuals. These
events represent CNVs that have been reported previously in the liter-
ature to directly cause a micro-deletion/-duplication syndrome and
therefore may directly explain any neurodevelopmental difficulties
experienced by individuals, irrespective of their SCT status.
Individual autosomal CNVs with a sum_pLI score of ≥0.9, regard-
less of size, were reported as pathogenic if they either overlapped
by at least 50% (and in the same CN state) with known CNV Syn-
drome region as reported in DECIPHER (https://decipher.sanger.ac.
uk/disorders#syndromes/overview), or with similar sized events
reported in DECIPHER and/or ClinVar as either pathogenic or likely
pathogenic, in line with current American College of Medical Genetics
(ACMG) guidelines (Nowakowska, 2017; South et al., 2013). While
the DECIPHER database is not specific to neurological phenotypes, it
is enriched for neurodevelopmental difficulties as these are common
features of CNV syndromes.
4 | RESULTS
A total of 125 SCT cases, composed of XXX (N = 40), XXY (N = 42),
and XYY (N = 43), and 181 comparison group (twin) individuals passed
both genotyping and CNV calling quality control (GenomeStudio,
PennCNV, and QuantiSNP). In total, 1,489 high-quality (with ≥50%
overlap between both algorithms and at least five consecutive SNPs)
autosomal events were detected.
4.1 | X chromosome CNV burden
We found no evidence of an increase in the number of X chromosome
CNVs in the SCT group compared to the comparison group. In total
13 high-quality X chromosome events were detected, three deletions
and five duplications were found to occur in eight comparison individuals
(N = 8/181, 3.97%), while two duplications and a deletion were found in
three XYY individuals and two duplications in two XXY individuals
(N = 5/85, 5.9%) (OR = 1.35, 95% CI = 0.43–4.26, p = 0.61, z = 0.514).
The XXX individuals (N = 40) were excluded from this analysis.
4.2 | Autosomal CNV burden
Table 3 shows comparative data for SCT versus comparison indi-
viduals on CNV burden for three measures: total number of auto-
somal CNVs, cumulative span of autosomal CNVs (in kb), and
total pLI scores across all autosomal CNVs per individual. Individ-
ual data points for CNV span and number of CNVs are shown in
Figure 1. A suggestion of a marginal excess in number of CNVs in
the SCT group was not statistically reliable when correction was
made for multiple tests. Notably, the comparison on our primary
measure, total pLI score (see Figure 2), did not reveal a reliable
group difference, either with or without the High Bias cases
included.
4.3 | Enrichment of pathogenic CNVs
We next sought to investigate whether the identified CNVs incorpo-
rated known pathogenic copy number events, as suggested by Le
Gall et al. (2017). This analysis was not pre-registered but was
suggested by reviewers. All CNV events overlapping ≥50% with
previously reported pathogenic microdeletion and duplications
reported in the DECIPHER database (Table 4). CNVs were described
if previously reported as either pathogenic or likely pathogenic,
and therefore clinically relevant according to ACMG criteria
(Nowakowska, 2017; South et al., 2013). Pathogenic CNVs were
identified in 15 individuals in total. This consisted of six identified in
the Comparison groups (3 XX and 3 XY, N = 6/181, 3.31%) and nine
in the SCTs (4 XYY, 4 XXY, and 1 XXX. N = 9/85, 10.59%; OR = 2.26,
95% CI = 0.7845–6.53, p = .1308). While there appears to be a mod-
est enrichment of pathogenic CNVs in the SCT cases, 10.58% com-
pared to 3.31% in the comparison group, this was not statistically
robust due to small numbers.
To investigate if carrying a pathogenic CNV resulted in a more
severe phenotype, individuals in whom a pathogenic or likely patho-
genic CNV was identified are indicated (P) in Figure 2. There is no visi-
ble trend indicative of a clear association between increased GNI and
carrying a pathogenic CNV.
TABLE 3 Mean (SD) measures for
autosomal CNV events for SCT and
Comparison groups, both for whole
sample, and for subset with low
ascertainment bias
SCT Comparison
p values*
Wilcoxon Perm. BY-corrected
N: Whole sample 125 181
CNVs per individual 5.21 (3.60) 4.56 (2.54) .106 .031 .170
CNV span (total kb) 325.4 (567.5) 256.3 (266.8) .282 .089 .214
Total pLI score 0.87 (1.28) 0.71 (1.13) .131 .117 .214
N: Low bias subset 65 50
CNVs per individual 5.22 (3.60) 4.62 (2.88) .195 .174 .825
CNV span (total kb) 364.7 (731.5) 285.5 (288.6) .628 .298 .825
Total pLI score 0.73 (1.33) 0.80 (1.29) .545 .615 1
*p values shown for pre-registered Wilcoxon test, as well as for permutation test. The final column shown values for the permutation test, with
Benjamini–Yekutieli correction for multiple comparisons.
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4.4 | Predicting global neurodevelopmental
impairment (GNI) from pLI scores
We conducted a pre-registered analysis, to test the prediction that SCT
versus comparison status would mediate the relationship between CNV
burden and phenotype. The relevant data are shown in Figure 2. The
analysis was implemented in a Poisson regression, using the whole
sample, with global neurodevelopmental index (GNI) as the dependent
variable, and SCT versus comparison status and total pLI score as pre-
dictors. Results are shown in Table 5. As expected, there was a substan-
tial effect of SCT/Comparison status on GNI. However, the pLI measure
of CNV burden did not predict outcome, and there was no interaction
with SCT/Comparison status. We observed a number of individuals with
a high GNI and a low total pLI score (indicating that the genes hit by the
CNVs were not dosage sensitive) or a low GNI score with CNVs that hit
genes with a high pLI (see Figure 2).
4.5 | Additional exploratory analyses
In response to reviewer suggestions for more analyses, we report in
Supplementary Material data similar to Table 3 (Table S1) but for each
trisomy separately, and data similar to Table 5 for two further pheno-
types, Language Factor, and PIQ (Table S2).
5 | DISCUSSION
In this article, we aimed to test two alternative models of heterogene-
ity with regards to CNVs in individuals carrying SCT. The “burden”
hypothesis suggests that individuals with SCTs may be at an increased
risk of neurodevelopmental disorder due to an increased burden of
CNVs across the genome. This is supported by previous investigations
by Rocca et al. (2016) and Le Gall et al. (2017). Alternatively, the “epis-
tasis” hypothesis suggests that the severity of neurodevelopmental
problems in SCT cases will be related to an increased burden of CNV
events affecting gene function. We find that neither of these hypoth-
eses could account for the variation in neurodevelopmental pheno-
types seen across SCT cases. Although we observed a slight increase
in the number of rare pathogenic CNVs in the SCT cases, this was not
significant and did not predict the severity of neurodevelopmental dis-
order. Similarly, we did not observe an excess of CNV burden in SCT
cases, nor did we find a relationship between CNV load and neu-
rodevelopmental outcomes. We did not find an enrichment of CNVs
on the X chromosome in SCT (XXY and XYY) individuals, failing to rep-
licate the findings of Rocca et al. (2016). Interestingly, our method
identified considerably fewer CNVs on the X chromosomes than the
autosomes; 3.97% of comparison individuals and 5.9% of SCTs carried
a CNV on chromosome X, in stark contrast to rates of 41% (XXY),
28.6% (XX), and 18.6% (XY) reported by Rocca et al. (2016). This strik-
ing discrepancy may be explained by the use of two different algo-
rithms (PennCNV and GenomeStudio) to call X chromosome CNVs in
this study compared to just PennCNV in Rocca et al. study. This dou-
ble analysis approach decreases false positives and increases confi-
dence in the calls made but may increase Type II error. Our method
was extremely conservative, and we therefore may have missed genu-
ine CNVs. This emphasizes that cross study comparisons are made dif-
ficult by methodological differences.
We did not find a reliable increase in overall burden of mean
autosomal CNVs carried by the SCT group (mean = 5.21, SD = 3.60)
F IGURE 1 Scatterplot showing total CNVs and CNV span (log kB)
for individual SCT and comparison cases The total CNV data points
have been jittered for visualization only
F IGURE 2 Scatterplot showing total pLI score and global
neurodevelopmental impairment for individual SCT and comparison
cases. Individuals found to carry a pathogenic CNV are indicated by P.
The global neurodevelopmental impairment data points have been
jittered for visualization
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compared to the comparison group (mean = 4.56, SD = 2.54): the vari-
ance within each group was substantially greater than the variance
between groups. It is important to note that when within-group variabil-
ity is very high, small differences may be masked, so that very large sam-
ples are required to give adequate power to detect them. Simpson
et al. (2015) found that language impaired individuals and their relatives
carried, on average, one additional CNV compared to a non-language
impaired group. In the current study, power was inadequate to detect
such a small effect against a background of substantial within-group
variation.
Across the autosomal CNVs called, we found only a small number
of potentially pathogenic events (as annotated by DECIPHER); 15 events
were flagged in total including six in comparison cases (3 XX and 3XY,
N = 6/181, 3.31%) and nine in SCTs (4 XYY, 4 XXY, and 1 XXX.
N = 9/85, 10.59%) (OR = 2.26, 95% CI = 0.7845–6.53, p = .1308).
Although this represents an enrichment in pathogenic CNVs in the SCT
group, the overall number of identified pathogenic events is small, and
therefore not statistically robust. These findings do not support those
reported by Le Gall where nine of the 14 SCT cases (64%) carried a
secondary pathogenic or likely pathogenic event. These discrepancies
may reflect a selection bias in the Le Gall study (where SCT cases were
selected to have severe neurodevelopmental syndromes and therefore
more likely to carry a known CNV) that was not as marked within the
present study and underlines the effects that sample selection can have
upon results.
At an individual level, the presence of these pathogenic CNVs may
explain the neurodevelopmental difficulties present in an individual. It is,
however, important to note that the presence of pathogenic CNVs does
not necessarily always result in the manifestation of a phenotype. Sever-
ity of symptoms can vary substantially between individuals, and unaf-
fected carriers are reported in the literature. For example the 16p13.11
recurrent micro-deletion is considered to be susceptibility locus for ASD
and developmental delay often accompanied by language difficulties,
but the phenotype is highly variable and unaffected carriers have been
reported (Hannes et al., 2009).
Given these results, and absence of statistically robust findings, we
do not find evidence to support the role of the burden model in relation
to “double-hits” in SCTs. Furthermore, we did not detect any association
between total pLI score and severity of neurodevelopmental impair-
ment, indicating that the two-hit model of CNV action does not explain
the range in severity of neurodevelopmental and language disorders
seen in SCT individuals as would be expected under an “epistasis”
model.
One strength of this study is that it includes SCT cases across clin-
ical categories (XXX, XXY, and XYY) that were both prenatally and
postnatally diagnosed as well as individuals with a wide range of neu-
rodevelopmental function (as described in Bishop et al., 2011). This
range extends the focus of previous studies (Le Gall et al., 2017; Rocca
et al., 2016) and provides scope to detect genetic differences that may
underlie neurodevelopmental outcomes. However, this study design
also results in limitations and methodological constraints, as presented
in the introduction and the discussion above. The sample size within
each clinical category or outcome group was individually small,T
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especially when genetic effects are expected to be heterogeneous, a
characteristic of CNVs (Veltman & Brunner, 2010). This heterogeneity
was apparent within individuals who carried pathogenic CNVs, not
all of whom presented with neurodevelopmental syndromes (see
Table 4). Similarly, it means that we cannot rule out the presence of
epistatic effects at the individual level. Although no single copy num-
ber event occurred in all SCT cases, it remains possible that specific
CNVs, and genetic variants in the wider sense, may act in an epistatic
manner. The characterization of these effects would require a genome
wide approach that affords power to consider interactions between
multiple genetic factors and environmental effects and was beyond
the scope of the current study.
In summary, this analysis does not support the view that there is
an increased burden of CNVs in individuals with SCTs, nor that CNVs
have disproportionate impact on neurodevelopmental phenotypes in
this population. Rare, pathogenic CNVs may contribute to the pheno-
type in some individuals with severe neurodevelopmental problems,
as was observed by Le Gall et al. (2017) but these do not account for
all neurodevelopmental difficulties within this cohort. Our data, which
includes cases detected prenatally and with a wide range of pheno-
typic presentations, suggest that secondary pathogenic events are not
a common occurrence in cases of SCT. Similarly, the wide variation in
phenotypes seen in this population cannot be explained by either the
“burden” hypothesis associated with excess CNV burden or the “epis-
tasis” model where a disproportionate impact is observed when CNVs
co-occur with a trisomy of the sex chromosomes.
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